Further advancements in Europe and the US increase capacity and process efficiency
● Construction of new clinical manufacturing facility in Des Plaines on schedule
● Established Skokie site with ongoing strong performance for biotech partners
● Infrastructure upgrades at Austrian site further streamline customers’ path to clinic
Ravensburg, April 14, 2026: Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announced significant progress in the continued expansion of its global clinical manufacturing network. With the ongoing scale-up of its Vetter Development Service offering, the company is taking important steps to provide necessary capacity, advanced technologies, and specialized expertise in response to rising demand for in-human trial material. By further strengthening its footprint in both Europe and the U.S., Vetter continues to position itself as a trusted long-term partner for biopharmaceutical innovators around the world.
“Our
continued global expansion reflects our holistic approach to supporting our
customers with their clinical development,” says Dr. Claus Feussner, Senior
Vice President of Vetter Development Service. “By investing in both technology
and capacity, we are working to provide our partners with the tailored early-stage
manufacturing services they need for their molecules to progress from the lab
to the clinic.”
U.S. facilities with strong performance and
major expansion efforts Vetter’s
U.S. presence continues to maintain its proven momentum. The company’s site in Skokie,
Illinois continues to serve as a cornerstone for global biotech partners in
their challenging journeys through clinical development. Since opening, the
site has supported over 140 customers and more than 350 compounds. Over 40% of
customers to date are start-ups or small companies with fewer than 50
employees.
To
build on this foundation, construction of Vetter’s new 160,000-square-foot
facility in Des Plaines, Illinois, is currently advancing on schedule. With the
steel structure nearly completed, interior work is set to begin soon. When
operational in 2029, the site will expand Vetter’s U.S. clinical manufacturing
capabilities and reinforce its long-term commitment to growth and serving
patients.
European site scales for customer demand Vetter’s
European clinical facility in Rankweil, Austria, has also achieved a new level
of operational maturity to support the increasing complexities of drug product
development. To accommodate steadily rising project volumes, the company is
making several infrastructure enhancements at the site designed to increase
capacity and streamline processes for the production of human Investigational
Medicinal Products.
These
improvements include the implementation of a new weighing room, an additional
compounding room within the aseptic production area, and increased capacity for
manual visual inspection. In addition, the site will benefit from new
cold-storage rooms, specialized freezer units for API storage, and an
additional incubator chamber to strengthen microbiological testing
capabilities.
By
strengthening its capabilities on both sides of the Atlantic, Vetter is
reinforcing its position as a global partner for comprehensive and cGMP-compliant
clinical development and filling. Aligning its European and U.S. clinical sites
supports harmonized processes, consistent quality standards, and the
flexibility required to meet the evolving needs of customers worldwide.
©Vetter Pharma International
GmbH: Vetter’s Des Plaines construction site is advancing on schedule (April
2026)
Find
the Vetter press kit and more background information here.
About Vetter Vetter is a leading Contract Development and Manufacturing
Organization (CDMO) with headquarters in Ravensburg, Germany, and production
facilities in Germany, Austria, and the US. As a global player, the independent
pharmaceutical service provider is also present in the Asia-Pacific markets of
Japan, China, South Korea and Singapore with sales locations. Around the world renowned
pharma and biotech companies benefit from decades of experience, high quality,
modern technologies, reliability, and commitment of its 7,300 employees. In
close collaboration with its customers, the Vetter team helps enable the supply
to patients all over the world with medicines, many of which are vital. The
CDMO provides support from drug product development through clinical and
commercial filling to a wide range of assembly and packaging services for
vials, syringes, and cartridges. With innovative approaches, Vetter develops
prefilled drug-delivery systems together with its customers to continuously
improve patient safety, comfort, and compliance. Vetter takes responsibility
for sustainable practices and operates as a socially and ethically responsible
corporate citizen. The CDMO is a member of the UN Global Compact and Science
Based Target initiative (SBTi) and received platinum status in the renowned
EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost
& Sullivan Customer Value Leadership Award and the recognition
of Best Managed Company emphasize Vetter’s commitment to sustainable
business. Founded in Ravensburg in 1950, the company remains family-owned to
this day. For more information, visit www.vetter-pharma.com and follow
Vetter on LinkedIn.
Contact Vetter Pharma International
GmbH Markus Kirchner Corporate Spokesperson / Media
Relations Eywiesenstrasse 5 88212 Ravensburg Germany Phone: +49 (0)751-3700-3729 E-mail: PRnews@vetter-pharma.com 
